董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Carter Pate | 男 | Director | 67 | 未披露 | 未持股 | 2021-05-19 |
| John Celentano | 男 | Director, Chairman of the Board | 61 | 6.10万美元 | 未持股 | 2021-05-19 |
| Carole S. Ben Maimon | 女 | Director | 62 | 4.33万美元 | 未持股 | 2021-05-19 |
| Timothy B. Sawyer | 男 | Director, Chief Executive Officer | 55 | 139.14万美元 | 未持股 | 2021-05-19 |
| Thomas J. Sabatino, Jr. | 男 | Director | 62 | 4.07万美元 | 未持股 | 2021-05-19 |
| William S. Marth | 男 | Director | 66 | 未披露 | 未持股 | 2021-05-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy B. Sawyer | 男 | Director, Chief Executive Officer | 55 | 139.14万美元 | 未持股 | 2021-05-19 |
| Philip K. Yachmetz | 男 | Chief Legal Officer and Corporate Secretary | 64 | 47.73万美元 | 未持股 | 2021-05-19 |
| Ernest R. De Paolantonio | 男 | Chief Financial Officer | 67 | 未披露 | 未持股 | 2021-05-19 |
董事简历
中英对照 | 中文 | 英文- R. Carter Pate
-
R. Carter Pate，他被提名为新董事。他此前曾担任MV Transportation公司（MV，美国最大的民营客运承包公司）的首席执行官（从2011年到2014年），并继续担任MV公司的独立战略顾问。从1996年到2011年，他曾任职PricewaterhouseCoopers公司（PwC）。从2010年到2011年，他担任PwC公司的资本项目和基础设施建设实践的美国和全球管理合伙人。从2008年到2010年，他曾担任PwC公司的卫生保健部门的全球和美国管理合伙人。从2005年到2008年，他曾担任负责政府服务的美国管理合伙人。从2004年到2005年，他曾担任PwC公司的美国市场管理合伙人。从2000年到2004年，他也曾担任PwC公司的金融咨询服务的管理合伙人。他曾担任PwC公司的美国重组实践的合伙人兼领导人（从1996年到2000年）。他此前曾担任Sun Television and Appliances公司（全国性零售商）的董事、临时总裁、首席执行官，也曾担任Sun Coast Industries公司的董事兼首席执行官，以及William Hudson Chemical Trading公司的财务董事。他也曾创立他自己的管理咨询公司。
R. Carter Pate, has served as a member of our Board of Directors since February 2021. Mr. Pate is the founder and Chief Executive Officer of Carter Pate, LLC, a Family Private Equity Investment Company, and has served as a board member to public and private boards of directors since 2014. He is the former Chief Executive Officer of Providence Service Corp DBA LogistiCare, the largest non-emergency medical logistics company for Medicare and Medicaid. Mr. Pate currently serves on the Board of Optioncare Health and was the Chairman of the Board of its predecessor, BioScrip Inc. He also serves as a member of the Board, the Chairman of its Compensation Committee, and a member of the Audit Committee for Advanced Emissions Solutions. Mr. Pate served as a member of the board of directors of Red Lion Hotels Corporation from May 2019 until March 2021. Prior to these roles, Mr. Pate had a career with PricewaterhouseCoopers spanning nearly two decades, including his service as a Global/United States Managing Partner of U.S. Advisory and later the Health Care practice leader. He is a co-author of The Phoenix Effect: Nine Revitalizing Strategies No Company Can Do Without, originally published in 2002 and translated into five languages. Mr. Pate holds certifications as a Certified Public Accountant and Certified Forensic Public Accountant. Mr. Pate obtained his undergraduate degree in Accounting from Greensboro College and a Masters in Accounting and Information Management from the University of Texas at Dallas. - R. Carter Pate，他被提名为新董事。他此前曾担任MV Transportation公司（MV，美国最大的民营客运承包公司）的首席执行官（从2011年到2014年），并继续担任MV公司的独立战略顾问。从1996年到2011年，他曾任职PricewaterhouseCoopers公司（PwC）。从2010年到2011年，他担任PwC公司的资本项目和基础设施建设实践的美国和全球管理合伙人。从2008年到2010年，他曾担任PwC公司的卫生保健部门的全球和美国管理合伙人。从2005年到2008年，他曾担任负责政府服务的美国管理合伙人。从2004年到2005年，他曾担任PwC公司的美国市场管理合伙人。从2000年到2004年，他也曾担任PwC公司的金融咨询服务的管理合伙人。他曾担任PwC公司的美国重组实践的合伙人兼领导人（从1996年到2000年）。他此前曾担任Sun Television and Appliances公司（全国性零售商）的董事、临时总裁、首席执行官，也曾担任Sun Coast Industries公司的董事兼首席执行官，以及William Hudson Chemical Trading公司的财务董事。他也曾创立他自己的管理咨询公司。
- R. Carter Pate, has served as a member of our Board of Directors since February 2021. Mr. Pate is the founder and Chief Executive Officer of Carter Pate, LLC, a Family Private Equity Investment Company, and has served as a board member to public and private boards of directors since 2014. He is the former Chief Executive Officer of Providence Service Corp DBA LogistiCare, the largest non-emergency medical logistics company for Medicare and Medicaid. Mr. Pate currently serves on the Board of Optioncare Health and was the Chairman of the Board of its predecessor, BioScrip Inc. He also serves as a member of the Board, the Chairman of its Compensation Committee, and a member of the Audit Committee for Advanced Emissions Solutions. Mr. Pate served as a member of the board of directors of Red Lion Hotels Corporation from May 2019 until March 2021. Prior to these roles, Mr. Pate had a career with PricewaterhouseCoopers spanning nearly two decades, including his service as a Global/United States Managing Partner of U.S. Advisory and later the Health Care practice leader. He is a co-author of The Phoenix Effect: Nine Revitalizing Strategies No Company Can Do Without, originally published in 2002 and translated into five languages. Mr. Pate holds certifications as a Certified Public Accountant and Certified Forensic Public Accountant. Mr. Pate obtained his undergraduate degree in Accounting from Greensboro College and a Masters in Accounting and Information Management from the University of Texas at Dallas.
- John Celentano
-
John Celentano，2015年3月起是本董事会一员。是医药行业的一名顾问。于2013年7月1日从Bristol-Myers Squibb Company退休，曾从2012年7月-2013年6月期间担任Amylin Integration Leader高级副总裁；2010年3月-2012年6月担任人力资源、公共事务和慈善事业高级副总裁。目前在私营企业JJ White Inc.和YourEncore Inc.董事会任职，以及在The Pennington School理事会任职。此外，还在一家国际非盈利卫生保健组织- Catholic Medical Mission Board理事会担任理事长。持有Delaware大学的学士学位和Drexel大学的工商管理硕士学位。
John Celentano, has served as a member of our Board of Directors since March 2015 and Chairman of the Board since July 2020. Mr. Celentano currently works as an advisor to the pharmaceutical industry. He retired from Bristol-Myers Squibb Company in 2013 where he held senior leadership positions including: President, Bristol-Myers Squibb Healthcare Group Mead Johnson Nutrition, ConvaTec, and Medical Imaging; Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe; and SVP of Human Resources. He serves on the Boards of privately held JJ White Inc. and the not-for-profit CMMB. Mr. Celentano holds a B.A. from the University of Delaware and an MBA from Drexel University. - John Celentano，2015年3月起是本董事会一员。是医药行业的一名顾问。于2013年7月1日从Bristol-Myers Squibb Company退休，曾从2012年7月-2013年6月期间担任Amylin Integration Leader高级副总裁；2010年3月-2012年6月担任人力资源、公共事务和慈善事业高级副总裁。目前在私营企业JJ White Inc.和YourEncore Inc.董事会任职，以及在The Pennington School理事会任职。此外，还在一家国际非盈利卫生保健组织- Catholic Medical Mission Board理事会担任理事长。持有Delaware大学的学士学位和Drexel大学的工商管理硕士学位。
- John Celentano, has served as a member of our Board of Directors since March 2015 and Chairman of the Board since July 2020. Mr. Celentano currently works as an advisor to the pharmaceutical industry. He retired from Bristol-Myers Squibb Company in 2013 where he held senior leadership positions including: President, Bristol-Myers Squibb Healthcare Group Mead Johnson Nutrition, ConvaTec, and Medical Imaging; Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe; and SVP of Human Resources. He serves on the Boards of privately held JJ White Inc. and the not-for-profit CMMB. Mr. Celentano holds a B.A. from the University of Delaware and an MBA from Drexel University.
- Carole S. Ben Maimon
-
Carole S. Ben Maimon，她担任我们的董事（2016年3月以来）。加入我们之前，她一直担任CSGB Consulting, LLC的顾问（2014年11月以来）。从2011年9月到2014年11月，她曾担任Impax Laboratories, Inc的通用产品部门的总裁。此前，她曾担任Qualitest Pharmaceuticals, Inc.的高级副总裁，负责公司战略（2009年7月至2010年7月）。任职Qualitest公司之前，她曾担任Alita Pharmaceuticals, Inc.（早期阶段私人持有的专业制药公司）的创始人、总裁和首席执行官、董事（从2006年9月到2009年6月）。她也曾担任Barr Pharmaceuticals公司的执行职务，以及董事会成员（2001年至2006年），其中包括Duramed Research, Inc.（Barr Pharmaceuticals, Inc.的全资子公司）的总裁兼首席运营官。她也曾担任Teva Pharmaceuticals USA公司的执行职务，在那里她曾担任高级副总裁，负责科学和公共政策（从2000年到2001年）、高级副总裁，负责研发（1996年至2000年）、Lemmon Company（Teva Pharmaceuticals, Inc.的全资子公司）的副总裁，负责医疗和管理事务（1993年至1996年）。她也曾担任 the Generic Pharmaceutical Association的董事会主席（从1999年到2002年）。她毕业于Thomas Jefferson Medical College，并获得了The University of Pennsylvania的生物学学士学位，在那里她以优异成绩毕业。她完成了Thomas Jefferson University的内科和肾脏学临床和科研训练。
Carole S. Ben Maimon, has served as a member of our Board of Directors since March 2016. Dr. Ben-Maimon is currently a director, President and Chief Executive Officer of Larimar Therapeutics, Inc. formerly Zafgen, Inc., which completed a business combination with Chondrial Therapeutics, Inc., effective May 28 2020 with Chondrial surviving as a wholly owned subsidiary of Larimar. Larimar Therapeutics, Inc. focuses on developing therapies for complex rare diseases, specifically Friedreich's Ataxia. Prior to the consummation of the merger and from December 2016 Dr. Ben-Maimon served as Chondrial Therapeutics, Inc.’s President, Chief Executive Officer and a member of its Board. Prior thereto and from 2014 to 2016 Dr. Ben-Maimon served as a consultant at CSGB Consulting, LLC. From September 2011 to November 2014 Dr. Ben-Maimon served as President of the generic products division of Impax Laboratories, Inc. Prior to that, she served as Senior Vice President, Corporate Strategy, at Qualitest Pharmaceuticals, Inc. from July 2009 to July 2010. Prior to her role at Qualitest, she served as Founder, President and Chief Executive Officer and director of Alita Pharmaceuticals, Inc., an early stage, privately held specialty pharmaceutical company, from September 2006 to June 2009. Dr. Ben-Maimon also held executive positions with and served as a member of the board with Barr Pharmaceuticals from 2001 to 2006 including as President and Chief Operating Officer of Duramed Research, Inc. (a wholly-owned subsidiary of Barr Pharmaceuticals Inc.). Dr. Ben-Maimon also held executive positions with Teva Pharmaceuticals USA, where she served as Senior Vice President, Science and Public Policy, from 2000 to 2001 Senior Vice President, Research and Development, from 1996 to 2000 and Vice President, Medical and Regulatory Affairs, with Lemmon Company (a wholly owned subsidiary of Teva Pharmaceuticals, Inc.) from 1993 to 1996. She served as the Chairman of the board of the Generic Pharmaceutical Association from 1999 to 2002. Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a Bachelor of Arts in biology from The University of Pennsylvania, where she graduated magna cum laude. She completed clinical and research training in internal medicine and nephrology at Thomas Jefferson University. - Carole S. Ben Maimon，她担任我们的董事（2016年3月以来）。加入我们之前，她一直担任CSGB Consulting, LLC的顾问（2014年11月以来）。从2011年9月到2014年11月，她曾担任Impax Laboratories, Inc的通用产品部门的总裁。此前，她曾担任Qualitest Pharmaceuticals, Inc.的高级副总裁，负责公司战略（2009年7月至2010年7月）。任职Qualitest公司之前，她曾担任Alita Pharmaceuticals, Inc.（早期阶段私人持有的专业制药公司）的创始人、总裁和首席执行官、董事（从2006年9月到2009年6月）。她也曾担任Barr Pharmaceuticals公司的执行职务，以及董事会成员（2001年至2006年），其中包括Duramed Research, Inc.（Barr Pharmaceuticals, Inc.的全资子公司）的总裁兼首席运营官。她也曾担任Teva Pharmaceuticals USA公司的执行职务，在那里她曾担任高级副总裁，负责科学和公共政策（从2000年到2001年）、高级副总裁，负责研发（1996年至2000年）、Lemmon Company（Teva Pharmaceuticals, Inc.的全资子公司）的副总裁，负责医疗和管理事务（1993年至1996年）。她也曾担任 the Generic Pharmaceutical Association的董事会主席（从1999年到2002年）。她毕业于Thomas Jefferson Medical College，并获得了The University of Pennsylvania的生物学学士学位，在那里她以优异成绩毕业。她完成了Thomas Jefferson University的内科和肾脏学临床和科研训练。
- Carole S. Ben Maimon, has served as a member of our Board of Directors since March 2016. Dr. Ben-Maimon is currently a director, President and Chief Executive Officer of Larimar Therapeutics, Inc. formerly Zafgen, Inc., which completed a business combination with Chondrial Therapeutics, Inc., effective May 28 2020 with Chondrial surviving as a wholly owned subsidiary of Larimar. Larimar Therapeutics, Inc. focuses on developing therapies for complex rare diseases, specifically Friedreich's Ataxia. Prior to the consummation of the merger and from December 2016 Dr. Ben-Maimon served as Chondrial Therapeutics, Inc.’s President, Chief Executive Officer and a member of its Board. Prior thereto and from 2014 to 2016 Dr. Ben-Maimon served as a consultant at CSGB Consulting, LLC. From September 2011 to November 2014 Dr. Ben-Maimon served as President of the generic products division of Impax Laboratories, Inc. Prior to that, she served as Senior Vice President, Corporate Strategy, at Qualitest Pharmaceuticals, Inc. from July 2009 to July 2010. Prior to her role at Qualitest, she served as Founder, President and Chief Executive Officer and director of Alita Pharmaceuticals, Inc., an early stage, privately held specialty pharmaceutical company, from September 2006 to June 2009. Dr. Ben-Maimon also held executive positions with and served as a member of the board with Barr Pharmaceuticals from 2001 to 2006 including as President and Chief Operating Officer of Duramed Research, Inc. (a wholly-owned subsidiary of Barr Pharmaceuticals Inc.). Dr. Ben-Maimon also held executive positions with Teva Pharmaceuticals USA, where she served as Senior Vice President, Science and Public Policy, from 2000 to 2001 Senior Vice President, Research and Development, from 1996 to 2000 and Vice President, Medical and Regulatory Affairs, with Lemmon Company (a wholly owned subsidiary of Teva Pharmaceuticals, Inc.) from 1993 to 1996. She served as the Chairman of the board of the Generic Pharmaceutical Association from 1999 to 2002. Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a Bachelor of Arts in biology from The University of Pennsylvania, where she graduated magna cum laude. She completed clinical and research training in internal medicine and nephrology at Thomas Jefferson University.
- Timothy B. Sawyer
-
Timothy B.Sawyer自2020年2月4日起担任首席执行官和董事会成员。在加入Teligent之前，从1993年到2009年，Sawyer先生在Barr Laboratories担任多个高级管理职位和市场营销与销售。从2008年到2009年，Sawyer先生担任全球通用销售与市场营销的执行副总裁，并领导着一个由25个国家的近2000名员工组成的团队。在Barr Laboratories工作之后，从2009年到2012年，Sawyer先生担任Mylan公司战略发展部的高级副总裁。最近，从2014年1月至2017年9月，Sawyer先生担任1-800-Doctors，Inc.零售医学总裁，并从2017年9月至2019年7月担任Geritrex，LLC的首席执行官，该公司是一家私募股权投资支持的非处方药开发商，制造商和营销商。Sawyer先生拥有里士满大学政治学学士学位。
Timothy B. Sawyer, has served as Chief Executive Officer and as a member of our Board of Directors since February 4 2020. Prior to joining Teligent, from 1993 through 2009 Mr. Sawyer held a variety of senior executive positions in general management, marketing and sales at Barr Laboratories. From 2008 through 2009 Mr. Sawyer served as Executive Vice President, Global Generic Sales and Marketing and led a team of nearly 2000 employees in 25 countries. Subsequent to his experience at Barr Laboratories, from 2009 through 2012 Mr. Sawyer served as Senior Vice President, Corporate Strategic Development at Mylan. More recently, from January 2014 through September 2017 Mr. Sawyer served as President, Retail Medicine of 1-800-Doctors, Inc. and from September 2017 through July 2019 he served as Chief Executive Officer of Geritrex, LLC, a private equity backed developer, manufacturer and marketer of generic over the counter pharmaceuticals. Mr. Sawyer holds a B.A. in Political Science from the University of Richmond. - Timothy B.Sawyer自2020年2月4日起担任首席执行官和董事会成员。在加入Teligent之前，从1993年到2009年，Sawyer先生在Barr Laboratories担任多个高级管理职位和市场营销与销售。从2008年到2009年，Sawyer先生担任全球通用销售与市场营销的执行副总裁，并领导着一个由25个国家的近2000名员工组成的团队。在Barr Laboratories工作之后，从2009年到2012年，Sawyer先生担任Mylan公司战略发展部的高级副总裁。最近，从2014年1月至2017年9月，Sawyer先生担任1-800-Doctors，Inc.零售医学总裁，并从2017年9月至2019年7月担任Geritrex，LLC的首席执行官，该公司是一家私募股权投资支持的非处方药开发商，制造商和营销商。Sawyer先生拥有里士满大学政治学学士学位。
- Timothy B. Sawyer, has served as Chief Executive Officer and as a member of our Board of Directors since February 4 2020. Prior to joining Teligent, from 1993 through 2009 Mr. Sawyer held a variety of senior executive positions in general management, marketing and sales at Barr Laboratories. From 2008 through 2009 Mr. Sawyer served as Executive Vice President, Global Generic Sales and Marketing and led a team of nearly 2000 employees in 25 countries. Subsequent to his experience at Barr Laboratories, from 2009 through 2012 Mr. Sawyer served as Senior Vice President, Corporate Strategic Development at Mylan. More recently, from January 2014 through September 2017 Mr. Sawyer served as President, Retail Medicine of 1-800-Doctors, Inc. and from September 2017 through July 2019 he served as Chief Executive Officer of Geritrex, LLC, a private equity backed developer, manufacturer and marketer of generic over the counter pharmaceuticals. Mr. Sawyer holds a B.A. in Political Science from the University of Richmond.
- Thomas J. Sabatino, Jr.
-
Thomas J. Sabatino, Jr.，2011年9月开始担任执行副总裁、法律总顾问兼公司秘书。2010年3月至2010年12月，他担任美国联合航空公司执行副总裁兼法律总顾问。2004年4月至2009年11月，他担任先灵葆雅公司执行副总裁兼法律总顾问。2011年11月开始他担任Unigene Laboratories董事，Unigene Laboratories是一家生物制药公司，专注于医用微蛋白质。2012年4月，他任联合博姿公司董事。
Thomas J. Sabatino, Jr., has served as a member of our Board of Directors since September 2017. Since February 15 2020 Mr. Sabatino has served as Executive Vice President, General Counsel and Corporate Secretary of Tenneco, Inc., a designer, manufacturer and marketer of automotive products for original equipment and aftermarket customers. From April 2016 to December 2018 Mr. Sabatino served as Executive Vice President and General Counsel of Aetna Inc. with worldwide responsibility for leading its legal operations, including formulating corporate legal policy. Prior to joining Aetna, Mr. Sabatino worked for Hertz Global Holdings, Inc., where he served as Senior Executive Vice President, Chief Administrative Officer and General Counsel. He joined Hertz in 2015 after serving as Executive Vice President, Global Legal and Chief Administrative Officer of Walgreens Boots Alliance. Previously, in 2010 Mr. Sabatino was Executive Vice President and General Counsel of UAL Corporation and United Airlines, Inc., and was Executive Vice President and General Counsel of Schering-Plough Corporation from 2004 through 2009. He also has held General Counsel positions at Baxter International and American Medical International. Mr. Sabatino has received numerous awards from his peers, including Inside Counsel’s Transformative Leader Award -2012 the National Bar Association Gertrude E. Rush Award -2013 and the Equal Justice Works Scales of Justice Award -2014 He is Co-Chair of the Board of Directors of the Humane Society of the United States. He serves on the Board of Overseers for the University of Pennsylvania Law School and the Board of Directors of the International Institute for Conflict Prevention and Resolution. Mr. Sabatino earned his law degree from the University of Pennsylvania and his undergraduate degree from Wesleyan University in Connecticut. - Thomas J. Sabatino, Jr.，2011年9月开始担任执行副总裁、法律总顾问兼公司秘书。2010年3月至2010年12月，他担任美国联合航空公司执行副总裁兼法律总顾问。2004年4月至2009年11月，他担任先灵葆雅公司执行副总裁兼法律总顾问。2011年11月开始他担任Unigene Laboratories董事，Unigene Laboratories是一家生物制药公司，专注于医用微蛋白质。2012年4月，他任联合博姿公司董事。
- Thomas J. Sabatino, Jr., has served as a member of our Board of Directors since September 2017. Since February 15 2020 Mr. Sabatino has served as Executive Vice President, General Counsel and Corporate Secretary of Tenneco, Inc., a designer, manufacturer and marketer of automotive products for original equipment and aftermarket customers. From April 2016 to December 2018 Mr. Sabatino served as Executive Vice President and General Counsel of Aetna Inc. with worldwide responsibility for leading its legal operations, including formulating corporate legal policy. Prior to joining Aetna, Mr. Sabatino worked for Hertz Global Holdings, Inc., where he served as Senior Executive Vice President, Chief Administrative Officer and General Counsel. He joined Hertz in 2015 after serving as Executive Vice President, Global Legal and Chief Administrative Officer of Walgreens Boots Alliance. Previously, in 2010 Mr. Sabatino was Executive Vice President and General Counsel of UAL Corporation and United Airlines, Inc., and was Executive Vice President and General Counsel of Schering-Plough Corporation from 2004 through 2009. He also has held General Counsel positions at Baxter International and American Medical International. Mr. Sabatino has received numerous awards from his peers, including Inside Counsel’s Transformative Leader Award -2012 the National Bar Association Gertrude E. Rush Award -2013 and the Equal Justice Works Scales of Justice Award -2014 He is Co-Chair of the Board of Directors of the Humane Society of the United States. He serves on the Board of Overseers for the University of Pennsylvania Law School and the Board of Directors of the International Institute for Conflict Prevention and Resolution. Mr. Sabatino earned his law degree from the University of Pennsylvania and his undergraduate degree from Wesleyan University in Connecticut.
- William S. Marth
-
William S. Marth，他曾一直担任Albany Molecular Research公司的董事（2012年6月以来），以及总裁兼首席执行官（2014年1月1日以来）。他曾担任Teva - Americas公司的总裁兼首席执行官，到2012年年底。他此前曾担任Teva North America公司的总裁兼首席执行官（从2008年1月到2010年6月），以及Teva USA公司的总裁兼首席执行官（从2005年到2008年）。此前，他曾担任Teva USA公司的执行副总裁，以及负责销售和营销的副总裁。他曾协助创立领先的专业制药公司Teva公司，使其最终被公认是全球仿制药生产商。他负责领导呼吸、神经学、肿瘤学和妇女的医疗保健部门，以及拉丁美洲和加拿大部门。他曾担任Teva公司的全球执行管理团队的一员，以及Teva Americas公司的董事会成员（从2007年到2013年）。他给这个职务带来丰富经验，涉及全球战略规划、投资者关系、研发、供应链和监管问题。他扮演着重要的角色，构建组织的120亿美元的业务，以及以68亿美元战略收购Cephalon公司，以74亿美元收购Barr Pharmaceuticals公司。加入Teva USA公司之前，他曾担任Bristol-Myers Squibb公司的Apothecon部门的多种职务。他于1977年获得the University of Illinois的药学学士学位，于1989年获得德弗里大学凯勒管理研究生院（ the Keller Graduate School of Management, DeVry University）的工商管理硕士学位。他是有执照的药剂师，并任职于多个其它董事会和委员会，包括The University of the Sciences in Philadelphia、the Board of Ambassadors for John Hopkins’ Project RESTORE。此外，他曾于2008年和2009年担任加纳港务局（the Generic Pharmaceutical Association，GPhA） 的董事会主席，并于2010年担任美国医院药剂师学会（the American Society for Health-System Pharmacists，ASHP）的董事会主席。
William S. Marth, has served as a member of our Board of Directors since February 2021. Mr. Marth serves as the Managing Partner of North Ocean Ventures, LLC, a consulting firm that helps pharmaceutical businesses realize their full potential. From 2018 to 2020 Mr. Marth has served as the President and Chief Executive Officer of North America and Europe for Avet Pharma Holdings Inc., a wholly owned subsidiary of Emcure Pharmaceuticals Ltd. Mr. Marth served as President and Chief Executive Officer of Albany Molecular Research Inc. from January 2014 until January 2018. Mr. Marth served as a Director of Albany Molecular Research Inc. and as chairman of its board of directors from June to December 2013. Prior to this, Mr. Marth served in various senior leadership roles at Teva Pharmaceutical Industries Ltd., including President and Chief Executive Officer of Teva Pharmaceuticals - Americas, as well as CEO of Teva North America and CEO of Teva USA. In addition, he was a member of Teva’s global executive management team from 2007 to 2012. Mr. Marth has served and continues to serve on a number of private and charitable Boards. Mr. Marth earned his Bachelor of Science in Pharmacy from the University of Illinois and his M.B.A. from the Keller Graduate School of Management, DeVry University. - William S. Marth，他曾一直担任Albany Molecular Research公司的董事（2012年6月以来），以及总裁兼首席执行官（2014年1月1日以来）。他曾担任Teva - Americas公司的总裁兼首席执行官，到2012年年底。他此前曾担任Teva North America公司的总裁兼首席执行官（从2008年1月到2010年6月），以及Teva USA公司的总裁兼首席执行官（从2005年到2008年）。此前，他曾担任Teva USA公司的执行副总裁，以及负责销售和营销的副总裁。他曾协助创立领先的专业制药公司Teva公司，使其最终被公认是全球仿制药生产商。他负责领导呼吸、神经学、肿瘤学和妇女的医疗保健部门，以及拉丁美洲和加拿大部门。他曾担任Teva公司的全球执行管理团队的一员，以及Teva Americas公司的董事会成员（从2007年到2013年）。他给这个职务带来丰富经验，涉及全球战略规划、投资者关系、研发、供应链和监管问题。他扮演着重要的角色，构建组织的120亿美元的业务，以及以68亿美元战略收购Cephalon公司，以74亿美元收购Barr Pharmaceuticals公司。加入Teva USA公司之前，他曾担任Bristol-Myers Squibb公司的Apothecon部门的多种职务。他于1977年获得the University of Illinois的药学学士学位，于1989年获得德弗里大学凯勒管理研究生院（ the Keller Graduate School of Management, DeVry University）的工商管理硕士学位。他是有执照的药剂师，并任职于多个其它董事会和委员会，包括The University of the Sciences in Philadelphia、the Board of Ambassadors for John Hopkins’ Project RESTORE。此外，他曾于2008年和2009年担任加纳港务局（the Generic Pharmaceutical Association，GPhA） 的董事会主席，并于2010年担任美国医院药剂师学会（the American Society for Health-System Pharmacists，ASHP）的董事会主席。
- William S. Marth, has served as a member of our Board of Directors since February 2021. Mr. Marth serves as the Managing Partner of North Ocean Ventures, LLC, a consulting firm that helps pharmaceutical businesses realize their full potential. From 2018 to 2020 Mr. Marth has served as the President and Chief Executive Officer of North America and Europe for Avet Pharma Holdings Inc., a wholly owned subsidiary of Emcure Pharmaceuticals Ltd. Mr. Marth served as President and Chief Executive Officer of Albany Molecular Research Inc. from January 2014 until January 2018. Mr. Marth served as a Director of Albany Molecular Research Inc. and as chairman of its board of directors from June to December 2013. Prior to this, Mr. Marth served in various senior leadership roles at Teva Pharmaceutical Industries Ltd., including President and Chief Executive Officer of Teva Pharmaceuticals - Americas, as well as CEO of Teva North America and CEO of Teva USA. In addition, he was a member of Teva’s global executive management team from 2007 to 2012. Mr. Marth has served and continues to serve on a number of private and charitable Boards. Mr. Marth earned his Bachelor of Science in Pharmacy from the University of Illinois and his M.B.A. from the Keller Graduate School of Management, DeVry University.
高管简历
中英对照 | 中文 | 英文- Timothy B. Sawyer
Timothy B.Sawyer自2020年2月4日起担任首席执行官和董事会成员。在加入Teligent之前，从1993年到2009年，Sawyer先生在Barr Laboratories担任多个高级管理职位和市场营销与销售。从2008年到2009年，Sawyer先生担任全球通用销售与市场营销的执行副总裁，并领导着一个由25个国家的近2000名员工组成的团队。在Barr Laboratories工作之后，从2009年到2012年，Sawyer先生担任Mylan公司战略发展部的高级副总裁。最近，从2014年1月至2017年9月，Sawyer先生担任1-800-Doctors，Inc.零售医学总裁，并从2017年9月至2019年7月担任Geritrex，LLC的首席执行官，该公司是一家私募股权投资支持的非处方药开发商，制造商和营销商。Sawyer先生拥有里士满大学政治学学士学位。
Timothy B. Sawyer, has served as Chief Executive Officer and as a member of our Board of Directors since February 4 2020. Prior to joining Teligent, from 1993 through 2009 Mr. Sawyer held a variety of senior executive positions in general management, marketing and sales at Barr Laboratories. From 2008 through 2009 Mr. Sawyer served as Executive Vice President, Global Generic Sales and Marketing and led a team of nearly 2000 employees in 25 countries. Subsequent to his experience at Barr Laboratories, from 2009 through 2012 Mr. Sawyer served as Senior Vice President, Corporate Strategic Development at Mylan. More recently, from January 2014 through September 2017 Mr. Sawyer served as President, Retail Medicine of 1-800-Doctors, Inc. and from September 2017 through July 2019 he served as Chief Executive Officer of Geritrex, LLC, a private equity backed developer, manufacturer and marketer of generic over the counter pharmaceuticals. Mr. Sawyer holds a B.A. in Political Science from the University of Richmond.- Timothy B.Sawyer自2020年2月4日起担任首席执行官和董事会成员。在加入Teligent之前，从1993年到2009年，Sawyer先生在Barr Laboratories担任多个高级管理职位和市场营销与销售。从2008年到2009年，Sawyer先生担任全球通用销售与市场营销的执行副总裁，并领导着一个由25个国家的近2000名员工组成的团队。在Barr Laboratories工作之后，从2009年到2012年，Sawyer先生担任Mylan公司战略发展部的高级副总裁。最近，从2014年1月至2017年9月，Sawyer先生担任1-800-Doctors，Inc.零售医学总裁，并从2017年9月至2019年7月担任Geritrex，LLC的首席执行官，该公司是一家私募股权投资支持的非处方药开发商，制造商和营销商。Sawyer先生拥有里士满大学政治学学士学位。
- Timothy B. Sawyer, has served as Chief Executive Officer and as a member of our Board of Directors since February 4 2020. Prior to joining Teligent, from 1993 through 2009 Mr. Sawyer held a variety of senior executive positions in general management, marketing and sales at Barr Laboratories. From 2008 through 2009 Mr. Sawyer served as Executive Vice President, Global Generic Sales and Marketing and led a team of nearly 2000 employees in 25 countries. Subsequent to his experience at Barr Laboratories, from 2009 through 2012 Mr. Sawyer served as Senior Vice President, Corporate Strategic Development at Mylan. More recently, from January 2014 through September 2017 Mr. Sawyer served as President, Retail Medicine of 1-800-Doctors, Inc. and from September 2017 through July 2019 he served as Chief Executive Officer of Geritrex, LLC, a private equity backed developer, manufacturer and marketer of generic over the counter pharmaceuticals. Mr. Sawyer holds a B.A. in Political Science from the University of Richmond.
- Philip K. Yachmetz
Philip K. Yachmetz自2008年11月起担任高级副总裁、总法律顾问和秘书；之前从2006年2月到2008年11月担任公司执行副总裁和首席业务官；2004年5月到2006年2月担任企业战略高级副总裁、总法律顾问和秘书。2000年到2004年Yachmetz担任Progenics Pharmaceuticals副总裁、总法律顾问和秘书。1998年到2000年他担任CytoTherapeutics（现名为StemCells，一家干细胞疗法发现公司）业务开发高级副总裁、总法律顾问和秘书。Yachmetz创立了Millennium Venture Management（一家为制药、医疗和高技术产业提供业务咨询和顾问服务的公司），并从1997年到1998年担任其总经理。1989年到1996年他在Hoffmann-La Roche（一家制药公司）担任法律职位。Yachmetz是新泽西州和纽约州律师协会认证律师。
Philip K. Yachmetz has served as our Chief Legal Officer and Corporate Secretary since July 2020. He leads the Legal, Human Resources, IT and Investor Relations teams. From 2015 through June 2020 Mr. Yachmetz, served as Chief Legal and Compliance Officer of Sovereign Medical Services, Inc., a privately held community healthcare system company. Prior to his position at Sovereign, Mr. Yachmetz held positions at Savient Pharmaceuticals, Inc. from 2004 to 2014 including Co-President, Chief Business Officer and General Counsel and Secretary from 2004 to 2014 and Senior Vice President, Executive Vice President, Chief Business Officer, General Counsel and Secretary from 2004 to 2013. Mr. Yachmetz holds a J.D. from the California Western School of Law and a B.A. from George Washington University.- Philip K. Yachmetz自2008年11月起担任高级副总裁、总法律顾问和秘书；之前从2006年2月到2008年11月担任公司执行副总裁和首席业务官；2004年5月到2006年2月担任企业战略高级副总裁、总法律顾问和秘书。2000年到2004年Yachmetz担任Progenics Pharmaceuticals副总裁、总法律顾问和秘书。1998年到2000年他担任CytoTherapeutics（现名为StemCells，一家干细胞疗法发现公司）业务开发高级副总裁、总法律顾问和秘书。Yachmetz创立了Millennium Venture Management（一家为制药、医疗和高技术产业提供业务咨询和顾问服务的公司），并从1997年到1998年担任其总经理。1989年到1996年他在Hoffmann-La Roche（一家制药公司）担任法律职位。Yachmetz是新泽西州和纽约州律师协会认证律师。
- Philip K. Yachmetz has served as our Chief Legal Officer and Corporate Secretary since July 2020. He leads the Legal, Human Resources, IT and Investor Relations teams. From 2015 through June 2020 Mr. Yachmetz, served as Chief Legal and Compliance Officer of Sovereign Medical Services, Inc., a privately held community healthcare system company. Prior to his position at Sovereign, Mr. Yachmetz held positions at Savient Pharmaceuticals, Inc. from 2004 to 2014 including Co-President, Chief Business Officer and General Counsel and Secretary from 2004 to 2014 and Senior Vice President, Executive Vice President, Chief Business Officer, General Counsel and Secretary from 2004 to 2013. Mr. Yachmetz holds a J.D. from the California Western School of Law and a B.A. from George Washington University.
- Ernest R. De Paolantonio
Ernest R. De Paolantonio，CPA, MBA，自2013年10月，他一直是我们的首席财务官，拥有在制药业超过35年的不同的财务和业务经验。从2008年到2013年，他曾担任CorePharma有限责任公司（一间私人专科仿制药公司）“核心”财务总监，直接参与金融和商业战略，建立产品的核心专有的标记组合。另外，从2002年到2008年， 他是财务管理与控制者，在Colombia Laboratories担任越来越重要的角色，负责业务发展与物流，包括为公司发布第一个商业产品的供应链管理。他曾担任多个中高层财务职位，在Taro Pharmaceuticals，他是公司管理者；在Watson Pharmaceuticals，他是财务执行董事，小组管理者，负责管理公司的的活性药物成分的供应链；在GlaxoSmithKline，他是小组管理者。他从莱康明学院收到他的文学学士，在圣约瑟夫大学读金融MBA，是有执照的注册会计师。
Ernest R. De Paolantonio has served as our Chief Financial Officer since April 15 2021 and will lead our Finance team. He has over 40 years of varied financial and business experience in the pharmaceutical industry. Most recently, Mr. De Paolantonio served as Chief Financial Officer of Fortovia Therapeutics Inc., a privately held healthcare company providing support to cancer patients and their families. Prior to his position at Fortovia, Mr. De Paolantonio served as Chief Financial Officer, Secretary and Treasurer at BioDelivery Sciences International, Inc., a publicly-held specialty pharmaceutical company from 2013 to 2019. Prior to Mr. De Paolantonio's position with BioDelivery Sciences, he served as the Chief Financial Officer of CorePharma LLC, a private specialty generic company, and held finance and controllers'positions in roles of increasing responsibility at Colombia Laboratories. Mr. De Paolantonio received his BA from Lycoming College; his MBA in Finance at Saint Joseph's University and is a licensed CPA.- Ernest R. De Paolantonio，CPA, MBA，自2013年10月，他一直是我们的首席财务官，拥有在制药业超过35年的不同的财务和业务经验。从2008年到2013年，他曾担任CorePharma有限责任公司（一间私人专科仿制药公司）“核心”财务总监，直接参与金融和商业战略，建立产品的核心专有的标记组合。另外，从2002年到2008年， 他是财务管理与控制者，在Colombia Laboratories担任越来越重要的角色，负责业务发展与物流，包括为公司发布第一个商业产品的供应链管理。他曾担任多个中高层财务职位，在Taro Pharmaceuticals，他是公司管理者；在Watson Pharmaceuticals，他是财务执行董事，小组管理者，负责管理公司的的活性药物成分的供应链；在GlaxoSmithKline，他是小组管理者。他从莱康明学院收到他的文学学士，在圣约瑟夫大学读金融MBA，是有执照的注册会计师。
- Ernest R. De Paolantonio has served as our Chief Financial Officer since April 15 2021 and will lead our Finance team. He has over 40 years of varied financial and business experience in the pharmaceutical industry. Most recently, Mr. De Paolantonio served as Chief Financial Officer of Fortovia Therapeutics Inc., a privately held healthcare company providing support to cancer patients and their families. Prior to his position at Fortovia, Mr. De Paolantonio served as Chief Financial Officer, Secretary and Treasurer at BioDelivery Sciences International, Inc., a publicly-held specialty pharmaceutical company from 2013 to 2019. Prior to Mr. De Paolantonio's position with BioDelivery Sciences, he served as the Chief Financial Officer of CorePharma LLC, a private specialty generic company, and held finance and controllers'positions in roles of increasing responsibility at Colombia Laboratories. Mr. De Paolantonio received his BA from Lycoming College; his MBA in Finance at Saint Joseph's University and is a licensed CPA.